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Background:  Shigella  sonnei  is  an  emergent  and major  diarrheal  pathogen  for which  there  is  currently  no
vaccine.  We aimed  to quantify  duration  of  maternal  antibody  against  S. sonnei  and  investigate  transpla-
cental  IgG  transfer  in a birth cohort  in southern  Vietnam.
Methods  and results:  Over  500-paired  maternal/infant  plasma  samples  were  evaluated  for  presence  of
anti-S.  sonnei-O  IgG and  IgM.  Longitudinal  plasma  samples  allowed  for the  estimation  of  the  median
half-life  of  maternal  anti-S.  sonnei-O  IgG,  which  was  43 days  (95%  conﬁdence  interval:  41–45 days).
Additionally,  half  of infants  lacked  a  detectable  titer  by  19  weeks  of  age.  Lower  cord  titers  were  asso-
ciated  with  greater  increases  in  S. sonnei  IgG over  the  ﬁrst year  of life, and  the  incidence  of  S. sonnei
seroconversion  was  estimated  to  be 4/100  infant  years.  Maternal  IgG titer,  the  ratio  of  antibody  transfer,
the  season  of  birth  and  gestational  age  were  signiﬁcantly  associated  with  cord  titer.
Conclusions:  Maternal  anti-S.  sonnei-O  IgG  is efﬁciently  transferred  across  the  placenta  and  anti-S.  sonnei-
O maternal  IgG  declines  rapidly  after  birth  and  is undetectable  after  5 months  in  the  majority  of  children.
Preterm  neonates  and  children  born  to mothers  with  low  IgG  titers  have  lower  cord  titers  and  therefore
may  be at greater  risk  of seroconversion  in infancy.
©  2016  The  Authors.  Published  by  Elsevier  Ltd.  This  is  an  open  access  article  under the  CC  BY license
(http://creativecommons.org/licenses/by/4.0/).
1. Introduction
The bacterial genus Shigella is a major contributor to the global
burden of diarrheal disease. This genus of enteric pathogens is
typically associated with disease in children under 5 years of age
in industrializing regions [1], and is estimated to be responsible
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for 100,000 deaths annually [2]. Shigella infections are charac-
teristically associated with dysentery (blood and mucus in the
stool) and can be severe in young children [3,4]. Of the four
Shigella species, Shigella ﬂexneri and Shigella sonnei predominate
worldwide [1]. S. ﬂexneri is traditionally associated with disease
in industrializing countries, whereas S. sonnei is more commonly
isolated in industrialized regions. However, this distribution is
changing. S. sonnei is globally emergent and replacing S. ﬂexneri
as the most common cause of bacterial dysentery [5,6]. This trend
may  be being exacerbated by resistance to common antimicro-
bials, with several recent reports of S. sonnei exhibiting resistance
against ﬂuoroquinolones and 3rd generation cephalosporins in
the USA, Vietnam and elsewhere [7–9]. Improved sanitation
and antimicrobial treatment remain the only current tools for
http://dx.doi.org/10.1016/j.vaccine.2015.12.047
0264-410X/© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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prevention and control as there are no licensed Shigella vac-
cines [10].
Neonates and infants are typically at increased risk from infec-
tious agents such as Shigella due to immaturity of the immune
system [11]. While neonates have some capacity for cell-mediated
immunity [12], humoral immunity is very limited in early life [13].
Antibody responses in neonates are shorter, delayed in onset and of
lower afﬁnity than those observed in healthy adults [14]. The trans-
fer of maternal IgG antibody to the fetus during pregnancy confers
short-term passive immunity and represents a primary mechanism
for protection against infectious diseases at birth [11]. Transport of
maternal antibody across the placenta to fetal capillaries is medi-
ated by the neonatal Fc receptor (FcRn) [15–17] and can be affected
by factors such as gestational age, maternal IgG concentration and
infection [18–21].
Maternally transferred IgG against S. sonnei in infancy has
not been substantially investigated. Work conducted in Israel
in the mid-1990s found that the concentration of anti-S. son-
nei lipopolysaccharide (LPS) IgG present in umbilical cord plasma
positively correlated with the concentration in maternal plasma
[22]. IgG against LPS, speciﬁcally the O-antigen component, is
the best described S. sonnei immune marker as it is the major
bacterial surface antigen exposed to the immune system during
infection. Although anti-S. sonnei-O IgG is not a deﬁnitive corre-
late of protective immunity [23], it is an indicator of some degree
of acquired immunity; lack of Shigella serotype speciﬁc antibody is
associated with an increased risk of symptomatic disease [24,25].
Furthermore, titers of anti-S. sonnei-O IgG rise signiﬁcantly after
symptomatic infection [22,26,27], with titers doubling 10 weeks
post-infection [26,28]. Previous work from Vietnam in the late
1980s showed that anti-S. sonnei-LPS and anti-S. ﬂexneri-LPS IgG
rise dramatically from birth, peak at 3–4 years of age and then
permanently plateau [29].
An understanding of the nature and duration of maternal anti-
body protection in infancy is important for determination of an
appropriate vaccination schedule when Shigella vaccines eventu-
ally become available. Additionally, although IgG titers against S.
ﬂexneri and Shigella dysenteriae type I in Vietnam were found to
be high in children and adults in the early 1990s [27,29], exposure
to Shigella has not been measured in a contemporary Vietnamese
population. As S. sonnei is now the predominant Shigella species
in Vietnam [30], we hypothesized there would be substantial evi-
dence of population exposure and S. sonnei maternal antibody
transfer in this rapidly industrializing country. Therefore, we  aimed
to quantify maternal anti-S. sonnei-O antibody decay using the
largest sample size to date, with over 500 paired mother and infant
plasma samples. We  also investigated transplacental IgG transfer
and determined the incidence of S. sonnei seroconversion in infancy
in southern, urban Vietnam.
2. Methods
2.1. Ethical approval
Written informed consent was required from all enrolled fam-
ilies. Ethical approval was granted from Hung Vuong Hospital,
Oxford Tropical Research Committee as well as the London School
of Hygiene & Tropical Medicine for the main cohort study. Ethical
approval was also granted from the Hospital for Tropical Diseases
in HCMC and OxTREC for the studies collecting acute and convales-
cent plasma samples from culture-positive Shigella and Salmonella
cases for ELISA validation.
2.2. Study population
The birth cohort population and methodology has been
described previously in detail [31]. Brieﬂy, mothers delivering at
Hung Vuong obstetric hospital in Ho Chi Minh City (HCMC) were
invited to enroll during either an antenatal visit in the ﬁnal month of
pregnancy or at the time of hospital admission for delivery. Children
born between January and December 2013 in HCMC were included
in the analysis presented here. Pregnant women were eligible if
they lived in district 8 of HCMC (a previously identiﬁed endemic
hotspot for Shigella [30]), were aged 16 years or older and were
HIV seronegative at the time of birth. Mothers answered a base-
line questionnaire and blood (umbilical cord and venous) samples
were collected in EDTA tubes. After delivery, infants were recalled
regularly for routine follow up visits. A 1 ml  EDTA blood sample
was collected at the 4, 9 and 12 month visits. All blood samples
were separated into cells and plasma and stored at −20 ◦C until
required.
2.3. S. sonnei anti-O antigen ELISA
Antibody (IgG and IgM) against S. sonnei O-antigen were mea-
sured using an enzyme-linked immunosorbent assay (ELISA) in
maternal, umbilical and longitudinally collected infant plasma
samples. Puriﬁed S. sonnei O-antigen was extracted as previously
described [32]. For the ELISA assays, 96-well microtiter plates
(Maxisorb; NUNC) were coated overnight with 0.5 g/ml S. son-
nei O-antigen in PBS pH 7.0 at 4 ◦C, plates were then washed
and blocked in PBS containing 5% skimmed milk powder for 2 h.
After washing, 100 l of each plasma sample (diluted at 1:200 in
PBS containing 1% skimmed milk) were added and plates were
incubated for 2 h at room temperature. IgG and IgM against S.
sonnei O-antigen were detected by incubation with alkaline phos-
phatase directly conjugated anti-human IgG/IgM for 1 h. Plates
were developed by p-nitrophenyl-phosphate solution (Sigma)
and were read at absorbance 405 nm and 490 nm by an ELISA
platereader (Microplate reader, Biorad). Each plate contained a 2-
fold serially diluted pool of anti-S. sonnei-O antigen human plasma
(primary concentration 1:200). A standard curve was generated
from the corresponding optical density (OD) and ELISA units using a
4-parameter logistic regression ﬁt. One ELISA unit (EU) was deﬁned
as the reciprocal dilution of the standard plasma that gave an
absorbance value equal to 1 in this assay. The ELISAs were done
in duplicate. Antibody (IgG and IgM) units in the cohort mem-
bers’ plasma were calculated relative to this standard each time the
assay was  performed. Acute and convalescent plasma samples for
the ELISA validation were derived from pediatric culture-positive
S. sonnei and Salmonella dysentery cases presenting to either the
Hospital for Tropical Disease in HCMC as part of another ongoing
study.
2.4. Statistical analyses
Geometric mean titers (GMT) were calculated to summarize
anti-S. sonnei-O IgG in maternal and cord plasma. Paired t-tests
were used to compare log10 titers between paired maternal/cord
samples. Analysis of variance (ANOVA) with Bonferroni correc-
tion for multiple comparisons was used to compare maternal and
cord log-transformed antibody titers within categorical groups. The
ratio of maternal transfer was compared across groups using the
Kruskal–Wallis (KW) test with Dunn’s test for multiple compar-
isons [33]. Linear mixed effects modeling was  used to assess the
trajectory of infant log10 titers from birth to 20 weeks to account for
within-participant association over time. The half-life of IgG titer
was calculated as the time at which the predicted IgG titer would
decrease by 50% from the cord blood titer. The population half-life
was derived using the formula:
−log10(2)
b1
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with b1 equal to the slope of the ﬁxed effect. The 95% conﬁdence
interval (CI) for the population level half-life was  derived from the
CI of the slope of the ﬁxed effect. Children with a 4-fold rise between
serial titers or those who were aged <6 months without a decrease
in IgG titer were censored after the time point prior to the increase
or no decrease, respectively [34].
A Kaplan Meier survival curve was generated to investigate
the time taken for titers to fall below a detectable threshold of
10.3 EU. This threshold value was determined by calculating the
mean titer value of the observation preceding a 4-fold rise in titer
in infants that had a 4-fold rise with a gap between pre and post-
seroconversion samples no greater than 24 weeks (n = 15). None
of the cord plasma titers and less than 1% (2/502) of the mater-
nal plasma samples had titers that fell below 10.3 EU. For the
Kaplan Meier estimation, infants were censored either when they
(1) dropped below 10.3 EU (2) had any rise in IgG titer or (3) were
lost to follow up. Finally, linear regression was  used to evaluate
the effect of covariates on anti-S. sonnei-O IgG cord titer as well
as the relationship between log10 cord titer and log10 increase in
titer between serial follow up visits. All analyses were performed
in STATA v13 (TX, USA) with the exception of the mixed effects
modeling which was performed in R (version 3.0.2) using the lme4
package [35]. Plots were made in R using the ggplot package v1.0.1
[36].
3. Results
3.1. ELISA validation
We  ﬁrstly validated the anti-S. sonnei-O ELISA in a pop-
ulation of Vietnamese children hospitalized with dysentery
with acute and convalescent plasma samples. All tested (7/7;
100%) stool culture-positive S. sonnei cases presenting to hos-
pital had >4 fold rise (median: 104-fold; range: 22–410)
in IgG titer regardless of the number of days between the
acute and convalescent samples (median: 116 days; range:
13–202). The IgM titers against S. sonnei O-antigen of the seven
responding children also increased dramatically (median: 9-fold,
range:3–64). Twenty culture positive Salmonella cases from the
same study did not generate an S. sonnei O-antigen IgG response
(median fold titer increase: 1.1, range: 0–2.0), with limited
IgM response as well (median: 1.4-fold, range: 0–58) (data not
shown).
3.2. Cohort baseline characteristics
Of the 503 infants enrolled into the birth cohort in 2013,
52% (260/503) were male, 4% (21/503) were born preterm (<37
weeks of gestation) and 5% (23/503) were of low birth weight
(<2.5 kg) as shown in Table 1. The median maternal age was 28
years (interquartile range (IQR): 25–31), with just under half of all
mothers (244/503; 49%) reporting at least a higher secondary edu-
cation. The median maternal gravidity was 2 (IQR: 1–3) and the
mean duration of infant follow up was 337 days (range: 1–399
days). A total of 58% (292/503) infants enrolled returned for all
three follow up appointments where a blood sample was col-
lected (Fig. 1A). A further 78% (393/503) returned for at least
two blood-draw appointments, and 86% (432/503) for at least
one follow up blood-draw appointment. There were no major
demographic or socioeconomic differences between the families
of infants who did not return for all four follow up visits (211/503;
42%) and those that did return for all four visits (292/503; 58%)
(Table 2).
Table 1
Baseline characteristics of 503 Vietnamese infants enrolled in the birth cohort in
2013.
Characteristic n (%), Median (IQR)
Male sex 260 (51.7)
Gestational age (weeks) 39 (38–40)
Preterm (<37 weeks) 21 (4.2)
Birth weight (kg) 3.15 (2.9–3.4)
Low birth weight (<2.5 kg) 23 (4.6)
Vaginal delivery 288 (57.3)
Breastfed during month 1
Exclusively 215 (43.0)
Plus formula 243 (48.6)
No, only formula 42 (8.4)
Gravidity 2 (1–3)
Maternal education
Lower secondary or below 255 (50.7)
Higher secondary or above 248 (49.3)
Maternal age (years) 28 (25–31)
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Fig. 1. Anti-S. sonnei-O antibody levels in the ﬁrst year of life in a cohort of 503
Vietnamese children. (A) Count of the number of assayed infant plasma samples at
different ages in the ﬁrst year after birth. Anti-S. sonnei-O IgG (B) and IgM (C) titers
shown over time for each individual in the cohort on a log10 scale.
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Table 2
Demographic and socioeconomic characteristics of infants with plasma samples
available from four follow up visits (0, 4, 9 and 12 months of age) and those who
attended less than four visits, n (%).
Characteristic <4 visits 4 visits pa
n = 211 n = 292
Vaginal birth 111 (52.6) 177 (60.6) 0.073
Male infant 113 (53.6) 147 (50.3) 0.477
Infant low birthweight 9 (4.3) 14 (4.8) 0.779
Any  previous children 128 (60.7) 185 (63.4) 0.539
Maternal age ≥28 years 109 (51.7) 150 (51.4) 0.949
Low maternal education 106 (50.2) 142 (48.6) 0.722
Household crowding 116 (55) 185 (63.4) 0.059
Infant cord log10 titer > 2.3b 122 (57.8) 151 (51.7) 0.175
Preterm (<37 weeks) 9 (4.3) 12 (4.1) 1.00
Breastfed during month 1
Exclusively 89 (42.6) 126 (43.3) 0.726
Plus formula 100 (47.8) 143 (49.1)
Formula + food 20 (9.6) 22 (7.6)
Mother ethnic minority 21 (10) 21 (7.2) 0.269
Father ethnic minority 26 (12.3) 24 (8.2) 0.129
Watersource
Piped home 144 (68.2) 208 (71.2) 0.73
Bottled 63 (29.9) 80 (27.4)
Other 4 (1.9) 4 (1.4)
a p-value derived from chi-square or Fisher’s exact test.
b Median.
3.3. The decay of maternal anti-S. sonnei-O IgG and incidence of
seroconversion
The anti-S. sonnei-O IgG and IgM titers in infants over the ﬁrst 12
months of life are shown in Figs. 1B and C, respectively. Using sam-
ples collected within 20 weeks of birth, we estimated the median
half-life of anti-S. sonnei-O IgG to be 43.2 days (95%CI: 41.9–44.5
days). As shown in Fig. 2, by 18.7 weeks (95%CI: 18.1–20.1 weeks)
50% of infants had undetectable levels of anti-S. sonnei-O IgG. A total
of 16 children had a >4-fold rise in anti-S. sonnei-O IgG titer in the
ﬁrst year after birth (3.2%), the majority of which occurred between
4 and 9 months (8/16, 50%), or 9 and 12 months (6/16, 38%) after
birth (Fig. 2). Critically, a higher fold-rise in anti-S. sonnei-O IgG
over the ﬁrst 12 months of life was associated with a lower cord
titer (p < 0.001; linear regression). There were 463.5 infant years of
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Fig. 2. Kaplan Meier curve showing the proportion of infants with detectable anti-S.
sonnei-O  IgG in the ﬁrst year after birth. The proportion of infants with detectable
anti-S. sonnei-O IgG censored by (1) when their titer dropped below 10.3 EU (see
methods), (2) had any detectable increase in IgG titer or, (3) lost to follow up. The
number of infants with detectable antibody at each time point are shown below the
x-axis.
follow up in this cohort, leading to a seroconversion rate (deﬁned
by >4-fold rise in titer) of 3.5/100 years of follow up in the ﬁrst
12 months of life. Two  children did not have a detectable decrease
in IgG titer between birth and 20 weeks of life (0.4%). Furthermore,
49/503 infants (10%) had a 2-fold rise in anti-S. sonnei-O IgG over the
course of the ﬁrst 12 months of life, the majority of which (25/49,
51%) occurred between 9 and 12 months of age. Out of the 503
infants enrolled in the cohort, 162 (32%) had a rise (any) in titer
over the ﬁrst year of life, which were more commonly detected
between 9 and 12 months of age (84/162; 52%).
3.4. Maternal antibody transfer
The geometric mean titers of anti-S. sonnei-O IgG in cord plasma
and maternal plasma were 234.1 EU (range: 21.6–3687.6 EU) and
167.4 EU (range: 3.75–2553 EU), respectively (Table 2). The median
ratio of cord:maternal plasma anti-S. sonnei-O IgG was  1.32 (range:
0.3–12.4) (Table 2). Anti-S. sonnei-O IgG titers in cord plasma
were consistently and signiﬁcantly higher than those in mater-
nal plasma (Table 2), with the exception of babies born preterm
(p = 0.71, paired t-test of log10 titers). The ratio of maternal transfer
in preterm babies (median: 1.13) was  signiﬁcantly lower than in
babies born 37–40 weeks (median: 1.35) (p = 0.02; KW). Further-
more, the transplacental transfer ratio in ﬁrst-pregnancy mothers
(median: 1.38) was moderately higher than in mothers that had had
previous pregnancies (median: 1.30, p = 0.066; KW). The maternal
transfer ratio was also slightly greater in younger mothers (<28
years) than in mothers ≥28 years of age (median: 1.36 versus
1.29, respectively; p = 0.065; KW). Finally, the transplacental trans-
fer ratio was signiﬁcantly higher in infants born in January–March
(median: 1.70) and in April–June (median: 1.90) compared to those
born in July–September (median: 1.14) and October–December
(median: 1.12) (Table 3).
3.5. Factors inﬂuencing anti-S. sonnei-O cord blood antibody
titers
Anti-S. sonnei-O cord IgG titer was  associated with several
covariates in a univariate analysis (Table 3). However, after con-
trolling for the effects of confounding in an adjusted analysis the
only covariates that remained signiﬁcantly associated with anti-
S. sonnei-O cord IgG titer were ratio of transplacental IgG transer,
maternal IgG titer and the season of birth. As shown in Fig. 3A, anti-
S. sonnei-O cord IgG titers in babies born in the ﬁrst half of the year
were higher than those born in the second half of the year. The ratio
of anti-S. sonnei-O IgG maternal transfer was also elevated in the
ﬁrst half of the year compared to the later months (Fig. 3B). Signif-
icantly, the ratio of transplacental transfer was  higher in mothers
with low IgG at the time of birth (Fig. 3C) (p < 0.001; linear regres-
sion of log10 maternal titers) (Table 4).
On additional analysis we found that maternal IgM increased
(Fig. 3D) from May  to July, plateauing in the later months of the
year, suggesting that some mothers were likely exposed to S. son-
nei at the time of birth during April-June. Maternal IgG levels did
not signiﬁcantly change throughout the year, although the titers
were generally high, suggesting previous and potentially sustained
exposure. The combination of low existing maternal IgG in some
mothers during April–June and the increased the ratio of transpla-
cental transfer during this period lead to an overall elevated anti-S.
sonnei-O IgG in babies born during this period, which may  be during
a period of increased seasonal S. sonnei transmission in HCMC.
4. Discussion
S. sonnei is an emergent and increasingly antimicrobial resis-
tant diarrheal pathogen. As such S. sonnei is a growing challenge in
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Table  3
Geometric mean titers (GMT) of anti-S. sonnei-O IgG in maternal and cord plasma and the ratio of cord:maternal IgG titer.
Category n Pairs Maternal IgG Cord IgG Median ratio Comparisona
GMT  (range) GMT (range) (range) p value Group
Total 503 167.4 (3.75–2553.7) 230.8 (0.22–3687.6) 1.33 (0–12.4)
Gestational age
<37 weeks (1) 21 190.8 (48.5–545.8) 197.4 (49.5–546.8) 1.13 (0.4–2.6) 0.019 1:2
37–40  weeks (2) 549 166.5 (3.7–2553.7) 232.1 (0.22–3687.6) 1.35 (0–12.4) 0.130 1:3
>40  weeks (3) 23 165.7 (22.3–1175.0) 237.7 (68.8–1163.3) 1.33 (0.6–6.2) 1.000 2:3
Sexb
Female 243 149.2 (8.2–2553.7) 209.9 (0.22–2140.9) 1.37 (0–12.4) 0.177
Male 260 186.4 (3.7–2524.2) 252.1 (23.1–3687.6) 1.28 (0.3–11.2)
Birthweight
<2500 g 23 150.8 (26.1–1280.1) 195.9 (42.4–2140.9) 1.25 (0.5–3.8) 0.515
≥2500 g 480 168.3 (3.7–2553.7) 232.6 (0.22–3687.8) 1.33 (0–12.4)
Gravidity
1  190 150.5 (3.7–2553.7) 216.7 (0.2–2824.8) 1.39 (0–12.4) 0.066
>1  313 178.6 (15.7–2524.2) 239.7 (23.1–3687.6) 1.3 (0.3–11.2)
Maternal ageb,c
<28 years 244 138.7 (3.7–1530.9) 204.5 (1.1–2824.8) 1.36 (0.3–12.4) 0.065
≥28 years 259 199.9 (20.6–2553.7) 258.6 (0.22–3687.6) 1.29 (0–8.3)
Maternal education
Lower secondary or below 255 179.9 (3.7–2553.7) 250 (26.7–3687.6) 1.29 (0.3–12.4) 0.449
Higher secondary or above 248 155.5 (15.7–2524.2) 212.5 (0.22–3206.5) 1.35 (0–11.2)
Maternal IgMc
≤1.37 253 158 (3.7–2553.7) 268.4 (22.1–2824.8) 1.66 (0.37–12.4) <0.001
>1.37 250 177.5 (15.7–2524.2) 203.8 (21.6–3687.6) 1.16 (0.3–11.2)
Seasonc
January–March (1) 89 148.2 (3.7–2553.7) 244.4 (34.1–2824.8) 1.7 (0.6–11.8) 0.024 1:2
April–June (2) 133 174.3 (8.2–1596.0) 358.3 (65.3–3687.6) 1.9 (0.4–12.4) <0.001 1:3
July–September (3) 161 162.6 (15.7–2524.2) 181.8 (22.1–3206.5) 1.14 (0.3–11.2) <0.001 1:4
October–December (4) 120 182.3 (33.5–1969.7) 187 (0.22–2123.2) 1.12 (0–5.8) <0.001 2:3
<0.001 2:4
1.000 3:4
a p-values comparing ratio of transfer between categories of each characteristic, p-values corrected for multiple comparisons are shown with groups indicated in parentheses
next  to the group name.
b Signiﬁcant difference in log10 titers of maternal plasma per category.
c Signiﬁcant difference between log10 titers of cord samples per category; titers are shown in ELISA Units (EU).
Vietnam and other similarly industrializing countries [5,6,37–42].
The aims of this study were: (1) to quantify the duration of maternal
IgG in infants, (2) to measure incidence of S. sonnei seroconver-
sion in the ﬁrst year of life and (3) to examine transplacental IgG
transfer during pregnancy. As S. sonnei vaccines are in development
[23], understanding the potential of maternal immunity in infants
Table 4
Univariate and multiple linear regression measuring the effect of different covariates
on the outcome of log10 cord anti-S. sonnei-O IgG titer.
Characteristic Cord blood IgG titer
Univariate Adjusted
Beta p Beta p
Cord:maternal IgG ratio 0.595 1.36 <0.001
Infant
Male sex 0.07 0.067 0.00 0.850
Gestational age 0.04 0.006 0.01 0.549
Birthweight 0.08 0.102 −0.01 0.504
Maternal
Age  0.01 0.001 0.00 0.246
Low  education −0.06 0.123 0.01 0.410
Gravidity 0.03 0.088 0.00 0.921
Log10 IgM −0.14 0.006 −0.01 0.798
Log10 IgG 0.76 <0.001 1.01 <0.001
Season
January–March 0.13 0.013 0.02 0.170
April–June 0.29 <0.001 0.08 <0.001
July–September 1.00 – 1.00 –
October–December 0.04 0.417 0.01 0.637
Beta values represent the slope of the linear association and p-values demonstrate
whether the slope is signiﬁcantly different from the null hypothesis of 0.
will be critical for evaluating future vaccine efﬁcacy and identifying
the infant groups that are most at risk of S. sonnei seroconversion
[4].
The estimated half-life of maternal anti-S. sonnei-O IgG (43 days,
95%CI: 42–45 days) is similar to that of Haemophilus inﬂuenzae (33
days), pertussis (36–40 days) and S. pneuomoniae (35 days) [43–45].
However, as the sampling was  infrequent in the early weeks after
birth these data should be interpreted with caution. Nevertheless, it
is apparent that maternal antibody wanes rapidly and by 5 months
of age the majority of infants had no circulating maternal antibody
and are likely at increased risk of infection. Correspondingly, evi-
dence of S. sonnei exposure in infants in our cohort suggests an
incidence of seroconversion of approximately 4/100 infant years of
follow up in HCMC. Yet given the known lack of general humoral
immune responses against polysaccharides during infancy [13], in
addition to loss to follow up, this seroconversion incidence is likely
an underestimate.
We found that lower cord titers were associated with higher
fold-increases in anti-S. sonnei-O IgG titer in the ﬁrst year of life in
our cohort, suggesting that neonates born with lower cord titers
are at increased risk of seroconversion during infancy. The most
important inﬂuences on anti-S. sonnei-O cord titer were mater-
nal IgG titer and the ratio of transplacental transfer, which were
inversely correlated. Such a relationship is due in part to saturation
of the Fc receptor, as IgG that is not bound is digested by lysoso-
mal  enzymes inside the syncytiotrophoblast [11,46]. The negative
relationship between maternal IgG concentration and transplacen-
tal transfer ratio has been suggested to demonstrate the existence
of a mechanism to protect the newborn through strengthening
the transfer of antibody when maternal levels are not optimally
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Fig. 3. Temporal anti-S. sonnei-O antibody cord titers and transplacental transfer dynamics. (A) Anti-S. sonnei-O IgG cord plasma titers shown by month of birth on a log10
scale. (B) The ratio of cord:matneral anti-S. sonnei-O IgG titer by month of birth. (C) Scatterplot showing the relationship between maternal anti-S. sonnei-O IgG titers and
the  ratio of cord:maternal plasma transfer. (D) Maternal anti-S. sonnei-O IgM titers shown by month of birth on a log10 scale.
protective [47,48]. Furthermore, it has been found that a higher
total maternal IgG concentration may  lead to reduced transfer efﬁ-
ciency of both total and speciﬁc IgG [21], with some suggestion of
receptor competition among antigen-speciﬁc IgG for the limited
number of placental Fc receptors available [20].
Neonates tended to have elevated anti-S. sonnei-O IgG titers
compared to mothers in our cohort. Such a phenomenon has been
reported for a variety of pathogens including Klebsiella pneumoniae,
Escherichia coli and Pseudomonas aeruginosa [18,47,49]. However,
neonates born preterm in this cohort did not have an increased
anti-S. sonnei-O titer relative to their mothers. As the majority of
IgG is acquired by the fetus during the last 4 weeks of pregnancy
[50], it follows that preterm neonates would lack maternal immu-
nity and are potentially at increased risk for infections in the ﬁrst
few months of life. Furthermore, we found that children born to
mothers with lower IgG titers had lower cord titers themselves and
are at increased risk of exposure.
Interestingly, we noted a seasonal pattern to both cord plasma
titers as well as the ratio of transplacental transfer in our cohort.
Cord titers and the transplacental transfer ratio were higher in the
second quarter of the year. Given the inverse relationship between
maternal IgG titer and transfer ratio, we propose that this period
may  represent a time of increased transmission and, therefore,
exposure to S. sonnei in HCMC. This hypothesis was  supported by
the observed increase in maternal IgM titer between May  and July
(representing acute infection), suggesting that mothers’ existing
immune response may  be naturally boosted during this time. If S.
sonnei transmission in HCMC is more common between April and
June then infants born in during this time are likely better equipped
against S. sonnei exposure at birth as the cord titers are highest
during this season. However, annual trends are difﬁcult to evaluate
from our yearlong dataset.
There were several limitations with this study. Firstly, the infre-
quent early blood samples from infants prevented high-resolution
temporal analyses regarding maternal half-life duration and sur-
vival analysis of the waning of maternal IgG. Next, the lack of
a similar cohort from a non-endemic area limits our ability to
fully interpret the serology data in an epidemiological context.
Furthermore, a lack of disease data prohibits an analysis of the pro-
tective effect of presence of antibody as well as a more detailed
analysis of anti-S. sonnei-O IgG and IgM response in infants after
infection. However, the major strength of this study is the cohort
design and relatively limited loss to follow up which enables
us to generalize our conclusions to Vietnamese infants in urban
HCMC. In the future, investigations into additional protective fac-
tors against Shigella, such as breastfeeding, may  be warranted
[51].
In summary, S. sonnei exposure is common in HCMC and mater-
nal IgG is readily transferred across the placenta, waning by 5
months of age in the majority of infants. In the event of licen-
sure of a sufﬁciently safe and immunogenic S. sonnei vaccine, it
would be prudent to vaccinate after the waning of maternal IgG
in settings such as HCMC. Furthermore, we found that neonates
have a higher concentration of IgG compared to mothers in most
cases, and the ratio of transplacental transfer is inversely related to
the maternal anti-S. sonnei-O IgG titer. Finally, we identiﬁed those
likely to be more at risk of S. sonnei exposure in infancy to include
preterm neonates and those born to mothers with lower IgG titers.
Therefore, appropriate monitoring and prevention strategies can
be targeted to such groups.
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